What podcasts say about Moderna
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Moderna
111 statements · 72 positive · 29 negative · 4 mixed · 6 neutral
Moderna and Merck’s neoantigen program leads the pipeline with the most Phase 3 trials.
“they're still clearly ahead in the pipeline. They have the most phase three trials.”
Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton OddsListen at 12:23
The Moderna and Merck program’s primary readout is not expected until 2028.
“this one's still not going to reach its primary readout till 2028.”
Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton OddsListen at 12:30
Moderna’s stock rose from $63 to above $174 in one day.
“Moderna was a $63 stock. The next day, it closed above $174”
Open the episode · NVIDIA Without Jensen, Anthropic IPO Risks & Moderna’s Cancer Vaccine 11/12/26Listen at 28:10
Moderna’s melanoma treatment showed a 42% patient improvement versus Keytruda.
“we were able to show a 42% improvement for patients.”
Open the episode · NVIDIA Without Jensen, Anthropic IPO Risks & Moderna’s Cancer Vaccine 11/12/26Listen at 32:03
Moderna’s melanoma vaccine data improves over time.
“We show that the data improves over time.”
Open the episode · NVIDIA Without Jensen, Anthropic IPO Risks & Moderna’s Cancer Vaccine 11/12/26Listen at 32:17
International COVID vaccine sales drove most of Moderna’s revenue increase
“Most of the revenue, though, is due to the increase in international COVID vaccine sales.”
Open the episode · 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026Listen at 22:29
Intismeran RCC data could materially move Moderna’s stock
“that's going to be a big mover for the stock, in my opinion.”
Open the episode · 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026Listen at 23:48
Moderna’s lipid-nanoparticle technology is well suited to propionic acidemia
“Moderna's technology is uniquely suited for this”
Open the episode · 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026Listen at 24:55
Positive propionic-acidemia results could expand Moderna into rare diseases
“if they see a positive effect here, then they're also going to be able to include rare disease into their franchise.”
Open the episode · 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026Listen at 25:30
Moderna’s high valuation depends on an unrealized, uncertain future
“the company's got such a high valuation now on a reality that doesn't quite exist yet and might never exist.”
Open the episode · 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026Listen at 27:50
Moderna's stock price has risen ahead of fundamentals.
“it's ahead of itself.”
Open the episode · Post-Midterm Playbook 11/4/26Listen at 28:45
Moderna has 39 vaccines and drugs in its pipeline.
“They've got 39 vaccines and drugs in the pipeline.”
Open the episode · Amazon in Focus as the Nasdaq Slides 10/3026Listen at 26:41
Moderna’s personalized vaccine currently takes about 42 days per dose to manufacture.
“it takes right now something like 42 days to make a dose”
Open the episode · Ep. 394 - Security concerns in U.S., China reshaping biotechListen at 26:56
Moderna is a high-quality company.
“I like Moderna. I think it's a terrific company.”
Open the episode · Mad Money w/ Jim Cramer 10/26/26Listen at 7:20
Moderna’s melanoma trial produced a recurrence-free survival hazard ratio of 0.58.
“the intent to treat recurrence-free survival hazard ratio was 0.58”
Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026Listen at 7:27
Two-year recurrence-free survival was 82.2% with treatment versus 70% for control.
“the two-year recurrence-free survival, it was 82.2% for the treatment group versus 70%”
Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026Listen at 7:50
Treatment-group adverse events caused more discontinuations than control-group events.
“14% of the adverse events in the treatment group led to discontinuations as compared to only 8%”
Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026Listen at 8:39
Moderna’s stock sell-off will probably continue.
“the sell-off is probably going to continue”
Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026Listen at 12:32
Non-small-cell lung cancer is Moderna’s major target indication.
“The big dog, or at least the gold, the gold. medal that they're going to be trying to achieve is non-small cell lung cancer.”
Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026Listen at 13:07
Moderna’s renal-cell-carcinoma trial is expected in early 2027.
“the renal cell carcinoma trial that I believe is going to be released in early 2027”
Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026Listen at 13:38
Positive renal-cell-carcinoma data could sustain Moderna’s valuation.
“if that seems to be particularly positive, then maybe you can sustain this valuation”
Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026Listen at 13:52
Speculation that Moderna cured cancer drove major stock volatility.
“the stock has been on this wild ride up and down, fueled by speculation that they cured cancer”
Open the episode · Moderna Drama, WSJ Mansion Section, Genetically Engineered Military Dogs | Thomas Wright, Kyle Schiller, Steven SchwartzListen at 1:40
Moderna’s phase-three trial succeeded but underwhelmed investor expectations.
“the phase three did succeed, but the results weren't as spectacular as investors had hoped.”
Open the episode · Why Moderna Tanked, MSG Employees Duped By Their Boss, The Mansion Section | Diet TBPNListen at 5:48
Moderna’s valuation had reached a level requiring nearly perfect results.
“it was getting to a point where you needed absolute perfection”
Open the episode · Episode 200 - October 23, 2026Listen at 7:40
Investors were seeking reasons to take profits after Moderna’s large increase.
“all that's going on here is people have tried to find a reason to to take profit for something that's gone up i don't know 200 300 400 depending where you measure it from”
Open the episode · Episode 200 - October 23, 2026Listen at 9:29
Moderna’s stock rose 25% over two weeks after Togi bought calls.
“Over the next two weeks, the stock went up 25%.”
Open the episode · Why Moderna Tanked, MSG Employees Duped By Their Boss, The Mansion Section | Diet TBPNListen at 9:59
Moderna’s stock remained above levels implied by the known trial success.
“this is clearly above what people thought this could do”
Open the episode · Episode 200 - October 23, 2026Listen at 10:46
Moderna’s stock price had moved above expectations before the pullback.
“this is clearly above what people thought this could do in the context of if you take a step out and look at it from a wider lens as opposed to what it was trading at the day before”
Open the episode · Episode 200 - October 23, 2026Listen at 10:46
Moderna shares fell 26% shortly after trial results leaked.
“Shortly after, the results were leaked and the stock crashed by 26%.”
Open the episode · Why Moderna Tanked, MSG Employees Duped By Their Boss, The Mansion Section | Diet TBPNListen at 11:16
Moderna’s stock fell 26% shortly after the trial results leaked.
“Shortly after, the results were leaked and the stock crashed by 26%.”
Open the episode · Why Moderna Tanked, MSG Employees Duped By Their Boss, The Mansion Section | Diet TBPNListen at 11:16
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.